Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
SANTA ANA, Calif., March 17, 2020 (GLOBE NEWSWIRE) -- NKMax America, a biotechnology company harnessing the power of the body's immune system through the development of Natural Killer (NK) cell therapies, today announced that Dr. Paul Song, Vice Chairman and Chief Medical Officer of NKMax America, has been selected to present at the upcoming NIH-AACR Cancer, Autoimmunity, and Immunology Conference on March 23-24, 2020.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The conference has been changed to a virtual conference by its organizers.
Presentation Title: Use of SNK-01 (Autologous Non-Genetically Modified Natural Killer Cells with Increased Cytotoxicity) in Combination with Pembrolizumab in Solid Tumors to Improve Tumor Response and Decrease Checkpoint Inhibitor Related Toxicity.
Dr. Song will discuss the significant role that natural killer cells play in improving overall tumor response to checkpoint inhibitors for both PD-L1 positive and PD-L1 negative tumors. He will also discuss their potential to reduce checkpoint inhibitor-related toxicity. Dr. Song will highlight NKMax America's proprietary natural killer cell expansion/activation technology and discuss NKMax's clinical experience with combination immune checkpoint-based therapy.
Buy at this blue line for a shot at trading profitably
There are so many indicators out there on when to buy and sell. Nic uses none. He looks at a chart and buys when a stock “pushes” off this blue line. What blue line? Find out on the next page. It’ll change how you make money from stocks. Click here for the details.
About NKMax America
NKMax America Inc. is a clinical stage biotechnology company dedicated to restoring and enhancing overall immune integrity. Our proprietary natural killer cell expansion and activation technology achieves infinite fold natural killer cell expansion with greatly enhanced cytotoxicity across its autologous, allogenic, and CAR-NK products which are all derived from peripheral blood. Our first in class autologous product, SNK-01, is currently in a Phase I clinical trial in advanced refractory solid tumors and in a Phase I/IIa combination trial with Keytruda in Stage IV non-small cell lung cancer. The company and its commercially licensed cGMP facility are headquartered in Santa Ana, California, USA.
For more information on the company, please visit www.nkmaxamerica.com
Contact:
Denise Chua, MBA, CLS, MT (ASCP)
Vice President, Marketing
949-396-6830
dchua@nkmaxamerica.com
Irina Koffler
Managing Director
LifeSci Advisors, LLC
646-970-4681
ikoffler@lifesciadvisors.com
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.